Indian billionaire investor Rakesh Jhunjhunwala says he's very upbeat about his country's growth potential after the country underwent a massive banking crisis and the rollout...Asia Economyread more
There's more pain ahead for the U.S. and China amid their bilateral trade dispute, according to one expert.China Politicsread more
The U.S. government on Monday temporarily eased some trade restrictions imposed recently on China's Huawei, a move that sought to minimize disruption for the telecom company's...Technologyread more
You know there's an underlying problem when investment firms start to cut exposure to a particular asset class.Commentaryread more
Stocks in Asia mostly recovered in Tuesday afternoon trade as investors cheered a reprieve in U.S.-China trade tensions surrounding Chinese telecommunications giant Huawei.Asia Marketsread more
The issue of corporate debt has surfaced as companies continue to use the low rates the Fed has provided to lever up their balance sheets.The Fedread more
A record 257.4 million travelers are expected to opt for U.S. airlines for travel this summer, the 10th consecutive annual increase, a trade group forecast on Tuesday.Airlinesread more
Huya, a Chinese live streaming platform focused on gaming, is looking to expand into the U.S. in the next couple of years, CEO Rongjie Dong told CNBC. The U.S. is expected to...Technologyread more
Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
Mall owners are increasingly building out food halls with local chef-driven eateries, sushi bars and premium coffee shops.Retailread more
While Trump's lawyers had argued that the committee's subpoena did not have a legitimate legislative purpose — and was therefore invalid — Mehta took a broader view.Politicsread more
Use of prescription opioids such as OxyContin or Vicodin fell at a record rate last year as the U.S. government cracks down on pharmacists and drugmakers that dispense the sometimes lethal painkillers, according to a report published Thursday.
Prescription opioid use in the U.S. was down 17% in 2018, marking the largest annual decline ever recorded, research firm IQVIA Institute for Human Data Science said. In 1992, prescription opioid use was at roughly 22 pain pills per U.S. adult per year and rose to a peak level of 72 pills per U.S. adult in 2011, IQVIA said. Since 2011, use has declined by 43% to 34 pills per adult.
The new data, unveiled in IQVIA's 2019 report on health-care trends, provides some hope for combating the nationwide opioid epidemic, which kills roughly 130 Americans every day. Just last month, a new study provided troubling news that the opioid crisis has led to a sharp increase in the death rate for overdoses by teens and young adults.
The Justice Department and U.S. lawmakers have been working to combat the epidemic, such as limiting painkiller prescriptions and punishing those seen as responsible for the epidemic.
On Wednesday, Sen. Elizabeth Warren, D-Mass., and House Oversight Committee Chairman Elijah Cummings, D-Md., unveiled a $100 billion proposal that would fund prevention services and provide resources to programs for those battling addiction and in recovery.
Last month, a former CEO of Rochester Drug Cooperative, one of the nation's largest drug distributors, was indicted on what prosecutors say are the first criminal charges against an executive of a drug company to stem from the opioid epidemic. In addition, the federal government reached a $20 million settlement with the company over its alleged role in the crisis.
Separately, federal prosecutors charged 60 doctors, pharmacists and other licensed medical professionals across five states in connection with illegally prescribing more than 32 million pain pills.
The indictments came as some 1,600 cases against OxyContin-maker Purdue Pharma and other opioid manufacturers are being consolidated and transferred before a judge in the Northern District of Ohio, and New York and other states begin their own massive legal fights.
The report Thursday showed prescriptions for lower-dose opioids remained stable, possibly because such painkillers are still perceived by physicians and patients as relatively safe, IQVIA said.
—CNBC's Meg Tirrell contributed to this report.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.